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STROMA TARGETS
CLINICAL REGIMENS PROVEN TO INCREASE SURVIVAL FOR 
PATIENTS WITH ADVANCED METASTATIC PANCREATIC CANCER
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FUEL UTILIZATION
CLINICAL AND MOLECULAR 
PROGNOSTIC FACTORS
GENOMIC VULNERABILITIES
Posterior location of 
pancreas, in close proximity to 
duodenum, common bile duct, celiac 
plexus, superior mesenteric artery (SMA), and portal vein, leads to 
late diagnosis as well as very bothersome symptoms of obstruc-
tion of biliary drainage, with infection, pain, and unresectability.
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Genetically engineered mouse 
models (e.g., the KPC model by 
Hingorani et al., 2005)
Primary patient-derived tumor 
xenografts (e.g., the PancXenoBank 
by Jimeno et al., 2009)
BREAKING TOLERANCE
Anti-CTLA-4
Anti-PD1
Anti-PD-L1
Anti-macrophage approaches
Mutation of BRCA2 – Chromosome 13q12
Peutz-Jeghers syndrome – autosomal dominant mutations in 
LKB1/STK11 on chromosome 19p13
Familial atypical multiple mole melanoma (FAMMM) syndrome – 
autosomal dominant mutation in CDKN2A tumor suppressor 
gene on 9p21
Hereditary nonpolyposis colorectal cancer (HNPCC) – autosomal 
dominant mutations in DNA mismatch repair genes
Familial kindreds - 2 or more first degree relatives
PALB2 mutation
Glucose (Aerobic glycolysis)
PI3K, AKT, LDHA, PKM2
Glutamine (Glutaminolysis) 
MYC, ASCT2, GLS, POL I
Cellular constituents (Autophagy) 
AMPK
Extracellular constituents
(Macropinocytosis) 
RAS, SRC
Hypoxia
Extracellular matrix 
Stellate cells - Vitamin D signaling
SPARC
(Secreted Protein Acidic, Rich in Cysteine)
Collagen
Hyaluronan
Hedgehog signaling
TGF-β signaling
Inflammation: 
NF-κB, IL-6, JAK1/2, COX2
High interstitial fluid pressure, 
growth induced solid stress
Mutations
KRAS, BRCA2, PALB2, TP53,
other DNA repair genes
Amplifications
ERBB2 (HER2/neu) 
Deletions (synthetic lethal possibility) 
SMAD4 (DPC4) 
CDKN2A (p16)
Hypermethylation
Inhibitors of DNMTs
Stem cell hypothesis
CD44, CD24, and epithelial-specific antigen (ESA) 
positive (Li et al., 2007)
Possible total time to evolve: 21-28 years
Exact cell of origin not clear
(candidates include epithelium, acinar cell, islet cell)
11.7 years: original gene mutation -> primary cancer 
6.8 years primary -> metastasis 
2.7 years appearance of metastases -> death. 
(Yachida et al., 2010)
*PanIN 
(Pancreatic 
intraepithelial 
neoplasia)
**IPMN 
(Intraductal 
papillary 
mucinous 
neoplasm)
Exocrine Pancreatic Cancer (95%)
Endocrine Pancreatic Cancer (5%)
Ductal adenocarcinoma (90%) 
Premalignant: Carcinoma in situ (*PanIN-3)
Mucinous cystadenocarcinoma (5%) 
(Acinar cell, pancreatoblastoma) 
Premalignant: **IPMN or mucinous cystadenoma
Islet cell     Carcinoid
Poor clinical prognostic factors
Poor molecular prognostic factors
Later stage
R1 resection (tumor at margin, 
lymph node positive)
Perineural invasion or vascular invasion
Poor performance status
Low serum albumin
Liver metastasis
Marker CA19-9 ≥ 59x ULN
Mutated SMAD4
Mutated TP53
Resectable (localized): Surgical resection with possible follow-up XRT plus 5-FU 
or gemcitabine or with 6 cycles of gemcitabine, median survival = 12-19 months
Metastatic disease: Chemotherapy – See treatment regimens in the 
table to the right, median survival with treatment = 6-11 months
No encasement of celiac axis or superior mesenteric artery (SMA)
Patent superior mesenteric – portal veins
No extra pancreatic disease
Locally advanced: XRT plus 5-FU or gemcitabine, or 
chemotherapy alone, median survival = 6-10 months
Encasement of arteries
Venous occlusion (SMV or portal)
No extra-pancreatic disease
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Pancreatic cancer can basically be divided into two major subtypes: adenocarcinoma, which is thought to arise in the exocrine portion of the pancreas (95% of cases), and rare 
endocrine tumors, which arise from islet cells (often designated as neuroendocrine tumors). This Snapshot concentrates on the most common and lethal type of adenocarcinoma 
of the pancreas: infiltrating ductal adenocarcinoma (designated here as pancreatic ductal adenocarcinoma or PDA).
Pancreatic cancer kills more than 37,000 people each year in the United States and more than 213,000 people worldwide. It has the worst 1 and 5 year survival rates of all 
cancers and, unfortunately, it is increasing in incidence. The highest rates of pancreatic cancer incidence are seen in industrialized and Western countries. In Europe, Nordic 
countries have the highest incidence rates (perhaps suggesting a role for Vitamin D). In the United States, the incidence is particularly high in Native Hawaiians, African Ameri-
cans, and Korean Americans. The incidence of pancreatic cancer also increases sharply after age 50. Pancreatic cancer in young patients is frequently familial; there is a 40% 
increase in risk for pancreatic cancer if there is familial pancreatitis. Other risk factors include diabetes, metabolic syndrome, pancreatitis, cigarette smoking, heavy alcohol 
consumption, infectious agents (H. pylori, hepatitis B), and gastric resection. Diets low in fruits and vegetables and involving high intake of meat (particularly barbequed) are also 
associated with increased risk.
This Snapshot is designed to outline the pathology of PDA, its association with inherited cancer syndromes, information regarding the origin and evolution of the disease, 
clinical and molecular prognostic factors, and clinical staging along with common treatment regimens that have been proven to increase survival. Clearly, new ways to attack 
pancreatic cancer are needed. Also outlined in the SnapShot are four possible ways to attack the disease via genomic vulnerabilities, PDA’s fuel utilization pathways, stroma 
targets, and breaking immune tolerance. These include some already discovered targets as well as some additional therapeutic possibilities. We hope that this cataloging of 
possibilities alongside the clinical aspects of the disease will help drive new approaches and ideas for development of new therapies and new methods for early detection of 
this awful disease.
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